Follow The Filings

MDGL Madrigal Pharmaceuticals

Madrigal Pharmaceuticals earnings company data as of 4:45 AM ET 11/6

History

1 period, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 3 Nov EPS 1.00 — —
Rev $405.1M $431.3M —

Insider trades

Open-market buys and sales by MDGL's executives, directors and 10% owners in the last 12 months, from their Form 4s

All MDGL insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $61.5M sold by 8 insiders under 10b5-1 plans
  1. William John Sibold CEO
    Planned sale
    $2.8M 5,221 shares at $542.39 2.6% of stake
    Traded Sep 11 Filed Sep 11
    ↗
  2. David Soergel Chief Medical Officer
    Planned sale
    $517K 1,042 shares at $495.74 9.4% of stake
    Traded Jun 1 Filed Jun 1
    ↗
  3. Richard S Levy Director
    Planned sale
    $2.9M 5,682 shares at $515.44 21% of stake
    Traded May 22 Filed May 22
    ↗
  4. Mardi Dier CFO
    Planned sale
    $575K 1,336 shares at $430.36 9.7% of stake
    Traded Mar 6 Filed Mar 6
    ↗
  5. Carole Huntsman Chief Commercial Officer
    Planned sale
    $282K 570 shares at $494.59 5.9% of stake
    Traded Jan 26 Filed Jan 26
    ↗
  6. Shannon T Kelley General Counsel
    Planned sale
    $215K 429 shares at $501.40 4.8% of stake
    Traded Jan 20 Filed Jan 20
    ↗
  7. Paul A Friedman Director
    Planned sale
    $154K 280 shares at $551.24 0.1% of stake
    Traded Jan 9 Filed Jan 13
    ↗
  8. Paul A Friedman Director
    Planned sale
    $12.8M 24,520 shares at $522.39 12% of stake
    Traded Jan 9 Filed Jan 13
    ↗
  9. Rebecca Taub Director
    Planned sale
    $132K 240 shares at $550.33 0.1% of stake
    Traded Jan 9 Filed Jan 13
    ↗
  10. Rebecca Taub Director
    Planned sale
    $9.6M 18,410 shares at $522.40 3.9% of stake
    Traded Jan 9 Filed Jan 13
    ↗
  11. Paul A Friedman Director
    Planned sale
    $13.7M 24,800 shares at $552.18 12% of stake
    Traded Dec 10, 2025 Filed Dec 12, 2025
    ↗
  12. Rebecca Taub Director
    Planned sale
    $10.3M 18,650 shares at $552.15 3.9% of stake
    Traded Dec 10, 2025 Filed Dec 12, 2025
    ↗
  13. Mardi Dier CFO
    Planned sale
    $2.4M 4,173 shares at $578.34 29% of stake
    Traded Dec 2, 2025 Filed Dec 3, 2025
    ↗
  14. Carole Huntsman Chief Commercial Officer
    Planned sale
    $590K 1,064 shares at $554.91 9.6% of stake
    Traded Nov 21, 2025 Filed Nov 21, 2025
    ↗
  15. Richard S Levy Director
    Planned sale
    $4.4M 8,500 shares at $520.96 29% of stake
    Traded Nov 13, 2025 Filed Nov 14, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 39 sales to cover taxes, 14 stock grants, 13 option exercises, and 1 gift.

SEC filings

Recent issuer filings from EDGAR, 19 shown.

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A DEFINITIVE PROXY STATEMENT Filing Doc
DEFA14A Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 3 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf